{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:33:18Z","timestamp":1793806398555,"version":"4.6.1"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real\u2010world database studies. Therefore, a larger comparative study was necessary to examine this signal. This study aimed to compare the cardiovascular risks of romosozumab with those of teriparatide in the overall population and in groups with a history of major adverse cardiovascular events (MACE). A new user cohort study was conducted using Japan\u2019s national claims database. Patients aged \u2265\u200940\u2009years who initiated romosozumab or teriparatide between March 2019 and March 2023 were analyzed. A multivariable Cox proportional hazards model was used to estimate the adjusted hazard ratio (aHR) for MACE. Subgroup analyses were conducted based on MACE history. A total of 251,219 romosozumab and 500,445 teriparatide users were analyzed (most common age group was 80\u201389\u2009years for both drugs; men: 9.33% for romosozumab and 14.14% for teriparatide). MACE occurred in 1853 romosozumab and 3427 teriparatide users, with incidence rates of 1.09 and 1.22 per 100 person\u2010years, respectively. The aHR (95% confidence interval [CI]) for romosozumab compared with teriparatide was 1.00 (0.94\u20131.06). In subgroup analyses based on MACE history, the aHRs (95% CI) for no history, for the one\u2010year period leading up to\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>0<\/jats:sub>\n                    , and for more than 1\u2009year before\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>0<\/jats:sub>\n                    were 1.01 (0.95\u20131.08), 0.93 (0.72\u20131.21), and 1.00 (0.85\u20131.18), respectively. In conclusion, no statistically significant difference in MACE risk was observed between romosozumab and teriparatide in Japan\u2019s national claims database, regardless of MACE history.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70142","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:14:55Z","timestamp":1763788495000},"page":"721-728","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan\u2019s National Claims Database"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3202-4869","authenticated-orcid":false,"given":"Hotaka","family":"Maruyama","sequence":"first","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3099-6523","authenticated-orcid":false,"given":"Eiko","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5424-1445","authenticated-orcid":false,"given":"Shinya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-8295","authenticated-orcid":false,"given":"Tomoaki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-2792","authenticated-orcid":false,"given":"Kazuhiro","family":"Kajiyama","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Regulatory Science Research Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihei","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"e_1_2_10_1_1","unstructured":"Pharmaceuticals and Medical Devices Agency.The list of SAKIGAKE designated drugs (only in Japanese)<https:\/\/www.pmda.go.jp\/files\/000267981.pdf>. Accessed September 29 2025."},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322"},{"key":"e_1_2_10_3_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Review Report (Evenity\u00ae). Pharmaceuticals and Medical Devices Agency<https:\/\/www.pmda.go.jp\/files\/000232793.pdf>. Accessed November 19 2024."},{"key":"e_1_2_10_4_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Revision in line with the Instructions for Package Inserts of Prescription Drugs PAB Notification No. 606. Pharmaceuticals and Medical Devices Agency<https:\/\/www.pmda.go.jp\/files\/000231400.pdf>. Accessed November 19 2024."},{"key":"e_1_2_10_5_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Summary of Investigation Results Romosozumab (genetical recombination). Pharmaceuticals and Medical Devices Agency<https:\/\/www.pmda.go.jp\/files\/000231403.pdf>. Accessed November 19 2024."},{"key":"e_1_2_10_6_1","unstructured":"Amgen Co. Ltd. Astellas pharma Co. Ltd.Request for proper use of drugs (Evenity\u00aeSubcutaneous Injection 105 mg Syringe) [in Japanese]. Pharmaceuticals and Medical Devices Agency <https:\/\/www.pmda.go.jp\/files\/000269781.pdf>. Accessed November 19 2024."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221144960"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081660"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07255-6"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae173"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002822"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.37737\/ace.24011"},{"key":"e_1_2_10_13_1","unstructured":"Research group for promoting use of medical information database under the research on regulatory science of pharmaceuticals and medical devices supported by the Ministry of Health Labour and Welfare Grant No. 20KC2007: FY2020\u2010FY2022 [in Japanese]<https:\/\/mhlw\u2010grants.niph.go.jp\/project\/149606>. Accessed January 8 2025."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5423"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.37737\/ace.22013"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3427"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02163"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206916"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000864"},{"key":"e_1_2_10_21_1","unstructured":"Fire and Disaster Management Agency.Current status of rescue<https:\/\/www.fdma.go.jp\/publication\/rescue\/items\/kkkg_r01_01_kyukyu.pdf>. Accessed September 29 2025."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036968"},{"key":"e_1_2_10_23_1","unstructured":"Statistics Bureau of Japan.Result of the population estimates \u2013 summary of the results (only in Japanese). <https:\/\/www.stat.go.jp\/data\/jinsui\/2024np\/pdf\/2024gaiyou.pdf>. Accessed September 29 2025."},{"key":"e_1_2_10_24_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Act on the Pharmaceuticals and Medical Devices Agency (Act No.192 of 2002) [in Japanese]<https:\/\/elaws.e\u2010gov.go.jp\/document?lawid=414AC0000000192> (Updated June 17 2022). Accessed October 10 2024."},{"key":"e_1_2_10_25_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Pharmacoepidemiological studies for drug safety assessment under MIHARI framework [in Japanese]<https:\/\/www.pmda.go.jp\/safety\/surveillance\u2010analysis\/0045.html>. Accessed October 10 2024."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01475-9"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01531-5"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2024.07.011"},{"key":"e_1_2_10_30_1","unstructured":"U.S. Food and Drug Administration.Label (Evenity). U.S. Food and Drug Administration<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s002lbl.pdf>. Accessed November 19 2024."},{"key":"e_1_2_10_31_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Labeling of EVENITY\u00aeSubcutaneous Injection 105mg Syringes [in Japanese]<https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112292_3999449G1025_2_01> Accessed January 20 2025."},{"key":"e_1_2_10_32_1","unstructured":"European Medicines Agency.Evenity: EPAR \u2013 product information. European Medicines Agancy<https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/evenity\u2010epar\u2010product\u2010information_en.pdf> (Updated September 10 2024). Accessed November 19 2024."},{"key":"e_1_2_10_33_1","unstructured":"Japan Osteoporosis Society.Guidelines for prevention and treatment of osteoporosis 2025 [in Japanese]<http:\/\/www.josteo.com\/data\/publications\/guideline\/2025_01.pdf>. Accessed September 4 2025."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0487-8"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05187-7"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70142","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:10:25Z","timestamp":1771312225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpt.70142"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70142","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}